Clinical trials: Oropharyngeal Cancer
Oropharyngeal Squamous Cell Carcinoma, HPV-mediated Oropharyngeal Squamous Cell Carcinoma
Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
The goal of this study is to evaluate if a shorter course of therapy can improve the quality of life in patients receiving radiation therapy after trans-oral robotic surgery.
- Trial name
- RAD RAPTORS (NCT07044635)
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Utah
Oral Cancer, Oropharyngeal Cancer
Speech-based AI-driven Diagnostics and Rehabilitation for Oral and Oropharyngeal Cancer.
Participants diagnosed with oral cancer, oropharyngeal cancer, or oral potentially malignant lesions, as well as healthy controls, had their speech audio recordings collected for the development and validation of AI-driven models…
- Trial name
- speech omics (NCT07347899)
- Where
- China
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- Yudong Xiao
HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck
Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma
The purpose of this study is to demonstrate that participants with HPV positive and hypoxia negative T1-2, N1-2c (AJCC, 7th ed.) oropharyngeal squamous cell carcinoma receiving a major de-escalated radiation therapy with 2 cycles…
- Trial name
- NCT03323463
- Testing
- F-FMISO PET/CT Scan, 30 Gy over 3 weeks, Cisplatin
- Where
- 10 sites in United States
- Volunteers
- 316 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
The goal of this clinical research study is to compare the use of MRI simulations to plan different doses of intensity modulated radiotherapy (IMRT) to the standard IMRT dose in patients with low risk human papilloma virus…
- Trial name
- NCT03224000
- Testing
- Modified Barium Swallow (MBS), Swallowing Questionnaire, Symptom Questionnaire
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Oropharynx Cancer
Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.
The goal of this clinical research study is to learn if minocycline can reduce the symptoms reported by patients with oropharynx cancer, nasopharynx cancer, or unknown primary cancer of head and neck, who receive treatment with…
- Trial name
- NCT01173692
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Oropharyngeal Squamous Cell Carcinoma (OPSCCA), HPV (Human Papillomavirus)-Associated
OPSCC N0 Nodal Control With Reduced IMRT
The dose of radiation most commonly used to treat oropharyngeal cancer results in side effects including sores in the mouth and throat, dry mouth and thick saliva, loss or altered taste, swallowing problems including pain or…
- Trial name
- NCT01891695
- Testing
- 39.6 Gy radiation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Paul W. Read, MD
Head and Neck Cancer
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving erlotinib after chemoradiotherapy may kill more tumor cells.
- Trial name
- NCT00079053
- Testing
- erlotinib hydrochloride, adjuvant therapy
- Where
- 2 sites in Canada
- Volunteers
- 19 people
- Sponsor
- NCIC Clinical Trials Group
Head and Neck Cancer, Infection
Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract
RATIONALE: It is not yet known which regimen of enteral nutrition is more effective in preventing infections in patients undergoing surgery for cancer of the upper aerodigestive tract.
- Conditions
- Head and Neck Cancer, Infection, Malnutrition
- Trial name
- NCT00765440
- Testing
- therapeutic nutritional supplementation
- Where
- France
- Volunteers
- 311 people
- Sponsor
- Centre Antoine Lacassagne
Mucositis, Oropharyngeal Cancer
Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With Oropharyngeal Cancer
Patients are asked to be in this study if have oropharyngeal cancer and will be treated with chemotherapy and radiation. This research is being done to find out if acupuncture can reduce the mouth inflammation and pain caused by…
- Trial name
- GCC1229 (NCT01883908)
- Testing
- Acupuncture with Seirin® needles, Usual medical care
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Maryland, Baltimore
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
The purpose of this study is to find out if the combination of two established anti-cancer therapies are beneficial in participants with Head and Neck Squamous Cell Carcinoma (HNSCC).
- Conditions
- Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT03370276
- Testing
- Nivolumab, Cetuximab
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Squamous Cell Carcinoma of the Oropharynx
Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life
The investigators are doing this study to learn about the quality of life patients have at the end of treatment. Some patients' cancers are related to human papilloma virus or HPV; others are not.
- Trial name
- NCT01181648
- Testing
- questionnaire and semi-structured interviews
- Where
- 6 sites in United States
- Volunteers
- 210 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Inserting the gene for p53 into a person's tumor may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
- Trial name
- NCT00003257
- Testing
- Ad5CMV-p53 gene
- Where
- 10 sites in United States
- Volunteers
- 39 people
- Sponsor
- Aventis Pharmaceuticals
HPV, Oropharynx Cancer
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC.
- Conditions
- HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy
- Trial name
- NCT05307939
- Testing
- HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer, Skin Reactions Secondary to Radiation Therapy
Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, but may cause skin irritation and inflammation. Biafine cream may be effective in lessening side effects caused by radiation therapy.
- Trial name
- NCT00006481
- Testing
- Biafine cream, quality-of-life assessment, radiation therapy
- Where
- 260 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Oropharynx Carcinoma
An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma
This is a prospective, observational study evaluating the effect and efficiency of different clinical treatments for patients with oropharyngeal carcinoma (OPC).
- Trial name
- NCT05341479
- Testing
- Surgery for early-stage OPC, RT for early-stage OPC, CRT for advanced OPC
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Oropharyngeal Tumor
A Study of Mucosal Sparing Proton Beam Therapy (PBT) in Resected Oropharyngeal Tumors
This study is an observational study evaluating the clinical outcomes of mucosal sparing proton beam therapy (PBT) after resection of favorable risk oropharyngeal cancer patients.
- Trial name
- NCT02736786
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Head and Neck Cancer
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00646659
- Testing
- cetuximab, carboplatin, cisplatin
- Where
- Belgium
- Volunteers
- 47 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oropharyngeal Dysphagia
The Passy Muir Swallowing Self Training Device
This is a device evaluation study to determine the optimal stimulation characteristics for using vibrotactile stimulation as a sensory triggering device for self retraining in patients with chronic moderate to severe dysphagia.
- Trial name
- PMSST (NCT01765673)
- Testing
- Vibrotactile stimulation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- James Madison University
HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
The purpose of this study is to learn more about a drug called Vorinostat (an experimental drug) in combination with chemoradiation.
- Conditions
- HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oropharynx
- Trial name
- HPV (NCT05608369)
- Testing
- Cisplatin, Radiation therapy, Vorinostat
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
A standard treatment for patients with head and neck cancer is radiation given with high doses of a chemotherapy drug called cisplatin, given every 3 weeks during the radiation.
- Trial name
- HPVOropharynx (NCT01855451)
- Testing
- Cetuximab, RT (70 Gy in 35 fractions), Cisplatin
- Where
- 16 sites in Australia, New Zealand
- Volunteers
- 189 people
- Sponsor
- Trans Tasman Radiation Oncology Group